help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrine Reviews, doi:10.1210/er.2008-0027
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Møller, N.
Right arrow Articles by Jørgensen, J. O. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Møller, N.
Right arrow Articles by Jørgensen, J. O. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*GLUCOSE
Endocrine Reviews 30 (2): 152-177
Copyright © 2009 by The Endocrine Society

Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects

Niels Møller and Jens Otto Lunde Jørgensen

Medical Department M, Aarhus University Hospital, and Clinical Institute, Aarhus University, DK-8000 Aarhus, Denmark

Correspondence: Address all correspondence and requests for reprints to: Jens Otto Lunde Jørgensen, Medical Department M, Aarhus University Hospital, Aarhus Sygehus, Norrebrogade 44, DK 8000 C, Aarhus, Denmak. E-mail: joj{at}ki.au.dk

In evolutionary terms, GH and intracellular STAT 5 signaling is a very old regulatory system. Whereas insulin dominates periprandially, GH may be viewed as the primary anabolic hormone during stress and fasting. GH exerts anabolic effects directly and through stimulation of IGF-I, insulin, and free fatty acids (FFA). When subjects are well nourished, the GH-induced stimulation of IGF-I and insulin is important for anabolic storage and growth of lean body mass (LBM), adipose tissue, and glycogen reserves. During fasting and other catabolic states, GH predominantly stimulates the release and oxidation of FFA, which leads to decreased glucose and protein oxidation and preservation of LBM and glycogen stores. The most prominent metabolic effect of GH is a marked increase in lipolysis and FFA levels. In the basal state, the effects of GH on protein metabolism are modest and include increased protein synthesis and decreased breakdown at the whole body level and in muscle together with decreased amino acid degradation/oxidation and decreased hepatic urea formation. During fasting and stress, the effects of GH on protein metabolism become more pronounced; lack of GH during fasting increases protein loss and urea production rates by approximately 50%, with a similar increase in muscle protein breakdown. GH is a counterregulatory hormone that antagonizes the hepatic and peripheral effects of insulin on glucose metabolism via mechanisms involving the concomitant increase in FFA flux and uptake. This ability of GH to induce insulin resistance is significant for the defense against hypoglycemia, for the development of "stress" diabetes during fasting and inflammatory illness, and perhaps for the "Dawn" phenomenon (the increase in insulin requirements in the early morning hours). Adult patients with GH deficiency are insulin resistant—probably related to increased adiposity, reduced LBM, and impaired physical performance—which temporarily worsens when GH treatment is initiated. Conversely, despite increased LBM and decreased fat mass, patients with acromegaly are consistently insulin resistant and become more sensitive after appropriate treatment.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
L. Moller, H. Norrelund, N. Jessen, A. Flyvbjerg, S. B. Pedersen, B. D. Gaylinn, J. Liu, M. O. Thorner, N. Moller, and J. O. Lunde Jorgensen
Impact of Growth Hormone Receptor Blockade on Substrate Metabolism during Fasting in Healthy Subjects
J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4524 - 4532.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Surya, J. F. Horowitz, N. Goldenberg, A. Sakharova, M. Harber, A. S. Cornford, K. Symons, and A. L. Barkan
The Pattern of Growth Hormone Delivery to Peripheral Tissues Determines Insulin-Like Growth Factor-1 and Lipolytic Responses in Obese Subjects
J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2828 - 2834.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society